Drug Target Insights最新文献_第4页

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report. sotorasib对KRAS p.G12C突变的非小细胞肺癌脑转移的活性:1例报告。

IF 2.7

Drug Target Insights Pub Date : 2023-01-01 DOI: 10.33393/dti.2023.2593

Alessandro Inno, Fabiana Marchetti, Matteo Valerio, Niccolò Giaj Levra, Filippo Alongi, Giovanni Foti, Stefania Gori

引用次数: 1

Efficacy of LAMP assay for Mycobacterial spp. detection to prevent treatment delays and onset of drug resistance: a systematic review and meta-analysis. LAMP法检测分枝杆菌预防治疗延误和耐药的疗效:一项系统综述和荟萃分析。

IF 2.7

Drug Target Insights Pub Date : 2023-01-01 DOI: 10.33393/dti.2023.2596

Gurvinder Singh Bumbrah, Sarika Jain, Zeeshan Fatima, Saif Hameed

{"title":"Efficacy of LAMP assay for Mycobacterial spp. detection to prevent treatment delays and onset of drug resistance: a systematic review and meta-analysis.","authors":"Gurvinder Singh Bumbrah, Sarika Jain, Zeeshan Fatima, Saif Hameed","doi":"10.33393/dti.2023.2596","DOIUrl":"https://doi.org/10.33393/dti.2023.2596","url":null,"abstract":"Background: Tuberculosis (TB) remains a deadly disease affecting one-third population globally. Long turnaround time and poor sensitivity of the conventional diagnostics are the major impediments for faster diagnosis of Mycobacterial spp to prevent drug resistance. To overcome these issues, molecular diagnostics have been developed. They offer enhanced sensitivity but require sophisticated infrastructure, skilled manpower and remain expensive.Methods: In that context, loop-mediated isothermal amplification (LAMP) assay, recommended by the WHO in 2016 for TB diagnosis, sounds as a promising alternative that facilitates visual read outs. Therefore, the aim of the present study is to conduct a meta-analysis to assess the diagnostic efficiency of LAMP for the detection of a panel of Mycobacterium spp. following PRISMA guidelines using scientific databases. From 1600 studies reported on the diagnosis of Mycobacterium spp., a selection of 30 articles were identified as eligible to meet the criteria of LAMP based diagnosis.Results: It was found that most of the studies were conducted in high disease burden nations such as India, Thailand, and Japan with sputum as the most common specimen to be used for LAMP assay. Furthermore, IS6110 gene and fluorescence-based detections ranked as the most used target and method respectively. The accuracy and precision rates mostly varied between 79.2% to 99.3% and 73.9% to 100%, respectively. Lastly, a quality assessment based on QUADAS-2 of bias and applicability was conducted.Conclusion: LAMP technology could be considered as a feasible alternative to current diagnostics considering high burden for rapid testing in low resource regions.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"17 ","pages":"78-89"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/e1/dti-17-78.PMC10249090.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9619511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir. 从依非韦伦切换到多替格拉韦后，伴有血脂异常的人类免疫缺陷病毒患者的脂质谱。

IF 2.7

Drug Target Insights Pub Date : 2023-01-01 DOI: 10.33393/dti.2023.2529

Supphachoke Khemla, Atibordee Meesing, Wantin Sribenjalux, Ploenchan Chetchotisakd

{"title":"Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir.","authors":"Supphachoke Khemla, Atibordee Meesing, Wantin Sribenjalux, Ploenchan Chetchotisakd","doi":"10.33393/dti.2023.2529","DOIUrl":"https://doi.org/10.33393/dti.2023.2529","url":null,"abstract":"ABSTRACT Introduction: Human immunodeficiency virus (HIV) infection and the long-term use of antiretroviral therapy, especially efavirenz (EFV)-based regimens, impact lipid profiles due to insulin resistance and lead to a higher risk of metabolic diseases. Dolutegravir (DTG) is an integrase inhibitor with better lipid profiles than EFV. However, data on treatment experience in Thailand are limited. The primary outcome was lipid profile changes at 24 weeks after switching therapy. Methods: We conducted a prospective, open-label, cohort study in people with HIV aged ≥18 years who had undergone at least 6 months of EFV-based therapy, had HIV-1 ribonucleic acid levels <50 copies/mL for ≥6 months before switching, and were diagnosed with dyslipidemia or had risk factors for atherosclerosis cardiovascular disease based on modified National Cholesterol Education Program Adult Treatment Panel III guidelines. Results: Sixty-four patients were enrolled. The mean age (standard deviation [SD]) was 48.20 ± 10.46 years, and 67.19% were male. At week 24, there were decreases from baseline in mean total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides. However, mean body weight and waist circumference had increased. Conclusions: DTG resulted in better lipid profiles after switching from EFV-based therapy, suggesting that this switch could benefit patients with a high risk of cardiovascular disease. However, it is essential to note that weight gain and increased waist circumference were also observed.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"17 ","pages":"45-53"},"PeriodicalIF":2.7,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/b8/dti-17-45.PMC10158613.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9433065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Association between cardiovascular diseases and periodontal disease: more than what meets the eye. 心血管疾病和牙周病之间的联系:不仅仅是眼睛看到的。

IF 2.7

Drug Target Insights Pub Date : 2023-01-01 DOI: 10.33393/dti.2023.2510

Bhavya Shetty, Ibrahim Fazal, Safiya Fatima Khan, Manjusha Nambiar, Khadijathul Irfana D, Rohit Prasad, Akshata Raj

引用次数: 0

Natural Products & Phytotherapeutics: why a new section? 天然产品与植物疗法:为什么要设立一个新版块?

IF 2.7

Drug Target Insights Pub Date : 2023-01-01 DOI: 10.33393/dti.2023.2548

Marcello Iriti

引用次数: 0

Antimicrobial resistance surveillance system mapping in different countries. 不同国家的抗菌药耐药性监测系统分布图。

IF 2

Drug Target Insights Pub Date : 2022-11-30 eCollection Date: 2022-01-01 DOI: 10.33393/dti.2022.2482

Ramendra Pati Pandey, Riya Mukherjee, Chung-Ming Chang

引用次数: 0

Anatomical and functional responses to single brolucizumab injection in neovascular age-related macular degeneration patients not responding to antiangiogenics: a case series 在抗血管生成药物无效的新生血管性年龄相关性黄斑变性患者中，单次brolucizumab注射的解剖和功能反应:一个病例系列

IF 2.7

Drug Target Insights Pub Date : 2022-03-24 DOI: 10.33393/dti.2022.2343

S. Zuccarini, Fabrizio Puce, Alessandro Crisà

{"title":"Anatomical and functional responses to single brolucizumab injection in neovascular age-related macular degeneration patients not responding to antiangiogenics: a case series","authors":"S. Zuccarini, Fabrizio Puce, Alessandro Crisà","doi":"10.33393/dti.2022.2343","DOIUrl":"https://doi.org/10.33393/dti.2022.2343","url":null,"abstract":"ABSTRACT Introduction: Neovascular age-related macular degeneration (nAMD) is treated with antivascular endothelial growth factor (anti-VEGF) drugs. However, resistance to anti-VEGF therapy is observed in some patients. Brolucizumab is a new-generation anti-VEGF drug for the treatment of nAMD, with proven efficacy in fluid resolution and long-lasting effects. Methods: We report here a case series of nAMD patients not responding to previous anti-VEGF therapy showing anatomical and functional response to a single intravitreal injection of brolucizumab. Results: Nine patients with nAMD, undergoing treatment with anti-VEGF therapy (aflibercept, bevacizumab, or ranibizumab) but with either fluid persistence or frequent fluid recurrences in retinal compartments, were switched to intravitreal brolucizumab and examined 4 weeks postinjection. No signs of active disease were observed in all but one patient, with complete retinal fluid resolution in seven patients. Central macular thickness and visual acuity significantly improved, and changes were sustained for up to 12 weeks in a subset of three patients. No adverse reactions were observed. Conclusions: This new anti-VEGF drug showed great efficacy since the first week from the injection with a significative reduction of subretinal fluid and rapid improvement of visual acuity. In conclusion, brolucizumab administered intravitreally appears to be an effective treatment in nAMD patients, leading to both early anatomical and functional improvements.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"16 1","pages":"6 - 11"},"PeriodicalIF":2.7,"publicationDate":"2022-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46116051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Success of 14-day triple and quadruple therapy for the control of Helicobacter pylori infections in Kohat district. 科哈特地区14天三联四联疗法控制幽门螺杆菌感染的成功。

IF 2.7

Drug Target Insights Pub Date : 2022-01-01 DOI: 10.33393/dti.2022.2481

Syed Fahim Shah, Sohail Aziz Paracha, Waheed Ullah, Iqbal Muhammad, Somaid Iqbal, Aisha Gul, Mudassir Hussain, Hafiz Ullah, Sadir Zaman

{"title":"Success of 14-day triple and quadruple therapy for the control of Helicobacter pylori infections in Kohat district.","authors":"Syed Fahim Shah, Sohail Aziz Paracha, Waheed Ullah, Iqbal Muhammad, Somaid Iqbal, Aisha Gul, Mudassir Hussain, Hafiz Ullah, Sadir Zaman","doi":"10.33393/dti.2022.2481","DOIUrl":"https://doi.org/10.33393/dti.2022.2481","url":null,"abstract":"ABSTRACT Introduction: Helicobacter pylori is an important medical pathogen present in more than half of the world’s population. Various treatment regimen are in use for the eradication of H. pylori, but due to the emergence of antibiotic resistance, its management is a big issue for clinicians. Methods: In this study all suspected cases that had visited District Headquarters Hospital Kohat were considered for screening of H. pylori infections. Preliminary information about their age, gender, general health conditions, occupation, etc. was taken for consideration. After recording initial signs and symptoms, samples were considered for H. pylori detection using stool antigen test and endoscopy. Fourteen-day proton pump inhibitor base triple and quadruple therapy were administered to each patient. Results: In total (n = 178), there were high numbers of positivity in patients aged below 30 years (82; 46.06%), most of whom belonged to rural areas. Conclusion: This study concludes that there were high numbers of positive patients aged below 30 years, and according to this study MEL (Metronidazole + Esomeprazole + Levofloxacin) is the most effective treatment regimen for the eradication of H. pylori.","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"16 ","pages":"49-53"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/37/55/dti-16-49.PMC9768595.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10459522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AMR research: a perspective from personal experience. 抗菌素耐药性研究:个人经验的视角。

IF 2.7

Drug Target Insights Pub Date : 2022-01-01 DOI: 10.33393/dti.2022.2545

Vijay Kothari

引用次数: 0

Current molecular approach for diagnosis of MRSA: a meta-narrative review. 当前MRSA诊断的分子方法:元叙述综述。

IF 2.7

Drug Target Insights Pub Date : 2022-01-01 DOI: 10.33393/dti.2022.2522

Sim Yi Xing, Lee Qiao Wei, Aisha Abushelaibi, Kok Song Lai, Swee Hua Erin Lim, Sathiya Maran

{"title":"Current molecular approach for diagnosis of MRSA: a meta-narrative review.","authors":"Sim Yi Xing, Lee Qiao Wei, Aisha Abushelaibi, Kok Song Lai, Swee Hua Erin Lim, Sathiya Maran","doi":"10.33393/dti.2022.2522","DOIUrl":"https://doi.org/10.33393/dti.2022.2522","url":null,"abstract":"ABSTRACT Introduction: Detection and diagnosis of methicillin-resistant Staphylococcus aureus (MRSA) are important in ensuring a correct and effective treatment, further reducing its spread. A wide range of molecular approaches has been used for the diagnosis of antimicrobial resistance (AMR) in MRSA. This review aims to study and appraise widely used molecular diagnostic methods for detecting MRSA. Methods: This meta-narrative review was performed by searching PubMed using the following search terms: (molecular diagnosis) AND (antimicrobial resistance) AND (methicillin-resistant Staphylococcus aureus). Studies using molecular diagnostic techniques for the detection of MRSA were included, while non-English language, duplicates and non-article studies were excluded. After reviewing the libraries and a further manual search, 20 studies were included in this article. RAMESES publication standard for narrative reviews was used for this synthesis. Results: A total of 20 full papers were reviewed and appraised in this synthesis, consisting of PCR technique (n = 7), deoxyribonucleic acid (DNA) Microarray (n = 1), DNA sequencing (n = 2), Xpert MRSA/SA BC assay (n = 2), matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) (n = 2), MLST (n = 4), SCCmec typing (n = 1) and GENECUBE (n = 1). Discussion: Different diagnostic methods used to diagnose MRSA have been studied in this review. This study concludes that PCR has been extensively used due to its higher sensitivity and cost-effectiveness in the past five years","PeriodicalId":11326,"journal":{"name":"Drug Target Insights","volume":"16 ","pages":"88-96"},"PeriodicalIF":2.7,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/77/1b/dti-16-88.PMC9906022.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10688896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0